Therabiopharma participará en Kyoto University Life Science Showcase 2020, San Diego.
Therabiopharma participó en Supply Side West 2019
El CEO de Therabiopharma presentó los últimos adelantos en nutraceuticals y fármacos en NCN (Nutrition Capital Network).
NUTRITION CAPITAL NETWORK
Nutrition Capital Network, a New Hope Network organization, facilitates financing and asset sales for growing companies and introduces investors to the next generation of brands and technology in the nutrition and health and wellness industries.
Therabiopharma (Japan Based Bio-Venture) Reports 10,000 Times Higher Curcumin Concentration in Bloodstream Clearly Demonstrates Strong Efficacies with/without Oxaliplatin in an Animal Study for Colon Cancer
Therabiopharma, a Japan based bio-venture, reports that CMG(Curcumin Monoglucuronide) has proven:
1. Same efficacy as Oxaliplatin for colon cancer without any adverse effects observed in Oxaliplatin treatment (Oxaliplatin is one of most frequently used colorectal cancer drugs worldwide).
2. Strong synergistic effect for colon cancer with Oxaliplatin.
3. Reduction of adverse effect of Oxaliplatin against hepatic functions. This may alleviate the sinusoidal obstruction syndrome by Therabiopharma’s research for colon cancer (HCT-116) bearing nude mice.
CMG reduces the side effects of Oxaliplatin on liver functions, such as increases in both ALT and AST, which are the indicators of liver damage.
At the same time, CMG clearly demonstrates its safety as:
No reduction in body weight of mice during the entire period of this test.
No reduction of number of white blood cells (WBC) and platelet (PLT) on Day 21.
These novel and significant efficacies have been achieved by the unique nature of the injectable CMG (curcumin monoglucuronide) which can release 10,000 times higher amounts of the curcumin free form in the bloodstream than normal curcumin powder intake orally (patent applied).
Therabiopharma Inc. focuses on the development of CMG as a drug for various refractory cancers with/without other approved cancer drugs. In particular, it has a strong focus for treatment/drug resistant cancers with multiple mutations of genes.
Associate Prof. Kanai, PhD, MD, Graduate School of Medicine (Oncology), Kyoto University and the scientific advisor of Therabiopharma said from these findings and results, “The data shown here demonstrated that the efficacy of curcumin monoglucuronide (CMG) is comparable to that of oxaliplatin in mouse model. Of note, none of the toxicities associated with cytotoxic anti-cancer drugs including myelosuppression (decrease of blood cells), liver damage, and body weight loss were observed in CMG arm, while they were evident in oxaliplatin arm. In daily clinical practice, oxaliplatin is widely used as a key drug for cancer treatment including colorectal, pancreatic, or gastric cancer in the world. However, liver damage called “Sinusoidal Obstructive Syndrome (SOS)” remains one of the serious adverse effects of oxaliplatin. SOS could hamper the efficacy of oxaliplatin and sometimes causes symptoms derived from liver failure. In this preclinical study, addition of CMG to oxaliplatin showed the enhanced efficacy of oxaliplatin as well as protective effect against oxaliplatin-induced liver damage. These data support the idea that combination of CMG with oxaliplatin could be a promising option in cancer treatment.”
Prof. Kakeya, PhD, Graduate School of Pharmaceutical Science, Kyoto University and the scientific advisor of Therabiopharma said for these significant achievements on the newly developed CMG «This curcumin monoglucuronide (CMG), a water-soluble prodrug of curcumin, could be highly expected as an innovative synthetic anticancer drug based on the natural product contained in turmeric.”
T. Hashimoto, Therabiopharma CEO, said “These findings from the animal test on CMG efficacy demonstrate CMG may play an important and innovative role on the battle with cancers, particularly against the drug/treatment resistant cancer in which the mutations of genes are frequently observed.
CMG (curcumin monoglucuronide) has also proven its ability to work with existing cancer drugs to materialize the synergistic effect.”
A new biotechnology venture company under collaboration with Kyoto University:
Leveraging the potential power of natural compounds/materials for medicine, diagnosis and nutraceuticals to substantiate “healthy aging” world-wide.
Nuestro últimos avances en la curcumina del tipo profármaco soluble en agua (CMG), será presentado en la conferencia GAP 2018 (Karolinska Institute in Sweden): Kanai, M., Imaizumi, A., Kakeya, H. «Development of a water-soluble curcumin monoglucronide (CMG) as a novel anticancer prodrug targeting KRAS-NF-kappa B signaling pathway», GAP (Global Academic Programs) conference, Stockholm, Sweden, May, 2018.
El efecto curativo sobre el cáncer de la curcumina del tipo profármaco soluble en agua (CMG), resultado de nuestra investigación conjunta con la universidad de Kioto, fue presentado por el doctor Masashi Kanai de la Escuela de posgrado de Medicina y Facultad de Medicina de Universidad de Kioto, en el decimoquinto simposio de la Sociedad Japonesa de la Oncología Médica celebrado en el 27 de julio de 2017. El resumen del contenido del mismo había sido publicado en el periódico Yomiuri del día anterior y despertó un gran interés entre los profesionales.
El centro de investigación de Thera Bio Pharma, Co., Ltd. se estableció recientemente en 608 East Wing, KSP Innovation Center Building en Kanagawa Science Park.